secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001104659-25-039478
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen board to replace Drs. Fernandes and Whittington at 2025 annual meeting
-----------------------------------------------------------------------------

- Prabha Fernandes, Ph.D., resigns; Marna C. Whittington, Ph.D., will not stand for re-election.
- Both departures effective at Ocugen's 2025 Annual Meeting of Stockholders.
- Board nominates Satish Chandran, Ph.D. (CEO, Prodigy Biotech) and Blaise Coleman (former CEO, Endo) to fill the vacancies.
- Dr. Chandran has prior roles as CEO at Somahlution, CTO at Pfizer Biotherapeutics; Mr. Coleman brings 20+ years pharma finance/ops experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/tm2513081d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-039478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer